Jiří Hradec,Eva Račická
Jiří Hradec
Type 2 diabetes mellitus represents a serious medical, social and economic problem, since it has become a pandemic in recent years, affecting up to 1/3 of the Czech population in old age. It is the clinically most significant metabolic dise...
[What is the significance of the phenomenon of hypertension in disguise in patients with type 2 diabetes mellitus treated for long-lasting hypertension?] [0.03%]
长期治疗高血压的2型糖尿病患者隐性高血压现象的意义在哪里？
Jiří Charvát
Jiří Charvát
"Hypertension in disguise" is quite frequent in the patients with diabetes mellitus. It leads to organ damage similarly as persistent hypertension and it is associated with an increased cardiovascular risk which can be reduced through effec...
[Early detection of ISHD in diabetic patients and determining the type of treatment] [0.03%]
[糖尿病患者ISHD的早期筛查及治疗类型确定]
Tomáš Kovárník,Kristýna Bayerová,Karel Kopřiva
Tomáš Kovárník
Diabetes mellitus is a major risk factor for the development of ischemic heart disease. Its prevalence in diabetic patients is reported to range broadly between 10-55 %. It is necessary to actively search for the presence of myocardial isch...
Jan Škrha,Pavel Škrha,Přemysl Frič
Jan Škrha
Diabetes mellitus and pancreatic cancer establish both-side relationship, one disease may have influence a development of the other. Pathogenic mechanisms sharing their relationship are overviewed. Early diagnosis may contribute to better p...
[XIGDUO - fixed combination of the active ingredients dapagliflozin and metformin] [0.03%]
西格朵(达格列净和盐酸二甲双胍的固定剂量复方制剂)
Tomáš Edelsberger
Tomáš Edelsberger
Fixed dose combination of two different drugs in the same or related indications are successfully used in various medical fields including diabetology. This article deals with the combination therapy comprising metformin and dapagliflozin i...
Jana Jiráčková,Alena Šmahelová
Jana Jiráčková
Victoza (liraglutide) is a modern antidiabetic drug of GLP1 (glucagone like peptide) analogue group; since 2009 registered in Czech republic. VICTOZA is used in therapy of type 2 diabetic patients with preserved endougenous insulin secretio...
Michal Vrablík,Eva Tůmová
Michal Vrablík
Diabetic dyslipidemia is a complex disorder associated with changes in lipid metabolism, which must be considered during care of the diabetic patient. Type 2 diabetes mellitus is a disease associated with a number of macrovascular and micro...
Ivan Tkáč
Ivan Tkáč
Pharmacogenetics is the study of how genes (individual genotypes) affect a persons response to drugs. At present, recommendations made about the treatment of some monogenic forms of diabetes are based on genetic diagnostics. The first studi...
[Clinical aspects of pharmacological treatment of diabetic neuropathy - cooperation with neurologists and diabetologists] [0.03%]
糖尿病性神经病变的药物治疗及与神经科和内分泌科医师的合作——临床方面
Denisa Janíčková Žďárská,Milan Kvapil
Denisa Janíčková Žďárská
The development and progression of symptomatic diabetic neuropathy (SDN) is linked to hyperglycemia. The effort to improve compensation of diabetes mellitus during therapy is therefore very important. This is where the cooperation between t...
[Obesity paradoxes] [0.03%]
[肥胖悖论]
Hana Rosolová
Hana Rosolová
Obesity (esp. abdominal type) was still considered as a risk factor for cardiovascular disease. During the last decade has a new phenomenon appeared: "obesity paradox", i.e. patients with high BMI die less frequently than patients with low ...